News | April 07, 2010

Study Finds Ventilatory Efficiency More Accurately IDs Heart Transplant Candidates

April 7, 2010 – A study concludes ventilator efficiency (VE/VCO2 slope) is more accurate than the current listing criteria for heart transplantation in identifying patients likely to derive a survival benefit from such intervention. The results were recently published in Circulation Heart Failure, a journal of the American Heart Association.

The study conclusions reinforce the science behind the Shape-HFTM Cardiopulmonary Exercise Testing system, which measures ventilation parameters including ventilatory efficiency. Cardiopulmonary exercise testing (CPX) has been used for many years to help doctors understand the severity and prognosis in patients with chronic heart failure. Peak CPX testing can guide physicians in their clinical decision-making, but conducting CPX tests at such levels comes with its own set of problems such as maximal physical effort by the patient, specialized training, and interpretation challenges.

A total of 663 chronic heart failure patients who underwent cardiopulmonary exercise testing were tracked for cardiac mortality and heart transplantation. Symptom-limited CPX testing was performed on all patients. Oxygen uptake (VO2), carbon dioxide production (VCO2) and minute ventilation (VE) were measured on a breath-by-breath basis. Peak VO2 was defined as the highest 20- to 30-second average achieved during exercise. Patients were evaluated for the occurrence of death or heart transplantation. Follow-up was right-censored at three years.

Results showed that using a VE/VCO2 slope threshold instead of the current exercise criteria would classify 39 more subjects as high-risk, correctly identifying 19 more patients who died during follow-up, and 16 others who underwent transplantation. VE/VCO2 slope provided significant discrimination between the three years survival of both high- and low-risk patients relative to post-transplant patients. Re-analysis of survival data using death or heart transplantation as endpoint showed similar results.
The Shape-HF System is the first gas exchange testing device specifically designed for cardiology. It measures a patient’s functional capacity and quantifies the severity of dyspnea on exertion. The test takes 15 minutes and involves measuring ventilation parameters while the patient exercises on a treadmill at a very low intensity. The test also quantifies the heart rate response to exercise to determine if it is appropriate and can unmask potential co-morbidities that may adversely affect heart failure prognosis or therapy response.

Shape-HF measures cardiopulmonary gas exchange quickly without undue strain on the patient. It can be used in the office setting and provides real-time physiological assessment to help physicians elucidate the physiological underpinnings of dyspnea, objectively assess patient functional classification, monitor therapy response and progress, identify potential comorbidities, and optimize cardiac resynchronization therapy at exercise levels consistent with patient daily activity.

For more information: http://circheartfailure.ahajournals.org

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init